Acute Myeloid Leukaemia Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026 The global acute myeloid leukaemia market is poised to value over US$ 1.5 billion by the end of 2026 and registering a CAGR of over 12% during the forecast period, 2019 to 2026 Radiation exposure, carcinogenic environmental components, unhealthy lifestyle and genetic mutations are mainly responsible for acute myeloid leukaemia (AML). The emergence of alternative AML therapeutics like Tyrosine Kinase Inhibitors, monoclonal antibodies and multidrug-resistant modulators provides significant benefits such as improved chances of early detection of cancer cells, improved quality and safety, reduction in relapse percentage, long term survival rates and so on. Some of the major factors impelling the growth of the global acute myeloid leukaemia market include: • High mortality rate owing to AML • Increasing relapse incidences • The limited response of present medical solutions to treat AML • Adverse effects of traditional treatments like tissue damage and loss of appetite in patients • A rise in the cancer-prone ageing population • Innovative drug development solutions using molecular biology • Propelling investments in pharmaceutical R&D by market players • Research incentives and rapid approvals by government bodies • Availability of tests that can predict the compatibility of a particular patient with drug or combination of drugs in achieving positive results Global Acute Myeloid Leukaemia Market Competitive Scenario The small and mid-sized pharmaceutical companies are exhibiting prominent presence with technologically innovative therapeutic techniques providing viable results. The overall market players pool is competitive with major players like Teva Pharmaceuticals, Novartis AG and Pfizer. New drug pipelines, extensive clinical trials and collaborations to proliferate geographic presence would remain major attention area to gain a competitive advantage in coming years. Request a Sample Report @ https://www.futurewiseresearch.com/requestsample.aspx?id=177&page=requestsample Global Acute Myeloid Leukaemia Market Restraints + Lack of standardised treatments + Mounting preference towards stem cell replacement as an alternative solution + Heavily dominated market with the generics + High cost of therapeutic treatment processes coupled with safety apprehensions Global Acute Myeloid Leukaemia Market by Drug Class + Tyrosine Kinase Inhibitors + Hedgehog Pathway Inhibitors + Topoisomerase 2 Inhibitors + Others Tyrosine Kinase Inhibitors have undergone clinical evaluation for identification of recurring mutations in all phases of drug development, clinical trials (both single agents plus combination with chemotherapeutics) with promising anti-leukemic activity outcomes. The biomolecule induces the mobilization of the hematopoietic progenitors and stem cells in vivo which potentially aid the human biological system to kill cancer cells. Hence this drug class segment is estimated to dominate the global AML market over the next couple of years. Global Acute Myeloid Leukaemia Market by End User + Hospital + Clinic + Others Global Acute Myeloid Leukaemia Market by Region + North America + Latin America + Europe + Asia Pacific + Rest of the World North America leads the global acute myeloid leukaemia market due to existing patient base and healthcare setups. Besides, it has unique research and development infrastructure supported by government funds, leading pharmaceutical enterprises and healthcare organizations. This lead is further followed by the Europe region which is a hub for medical breakthroughs and skilled healthcare professionals. The APAC region is estimated to grow at a consistent CAGR in the near future due to increased awareness about AML, better healthcare infrastructure, rising disposable income and investment in healthcare innovation. Purchase a Copy of this Premium Research Report & Ask For Discount: https://www.futurewiseresearch.com/requestsample.aspx?id=177&page=askfordiscount Competitive Landscape: + Tier 1 players- established companies in the market with a major market share + Tier 2 players + Emerging players which are growing rapidly + New Entrants FutureWise Key Takeaways + Growth prospects + SWOT analysis + Key trends + Key data-points affecting market growth Objectives of the Study: + To provide with an exhaustive analysis on the Global Acute Myeloid Leukaemia Market by Drug Class, by End User and by Region + To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) + To evaluate and forecast micro-markets and the overall market + To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East + To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions + Profiling of companies to evaluate their market shares, strategies, financials and core competencies Table of Contents 1. Introduction a. Scope and Objective b. Assumptions and Acronyms c. Forecast Factors d. Research Methodology 2. Executive Summary a. Industry Cluster Analysis b. Competition Matrix c. Strategies Recommendations 3. Market Definition a. Report Scope (Inclusions & Exclusions) b. Market Segmentation 4. Global Acute Myeloid Leukemia Market Overview a. Global Acute Myeloid Leukemia Market Revenue (USD Mn) 5. Key Inclusions a. Porter’s Five Force analysis b. Market Dynamics c. Industry Trends d. Regulatory Guidelines e. Opportunities in Acute Myeloid Leukemia 6. Competition Dynamics a. Company Share Analysis (2018) b. Top 10 Product Pricing by Region 7. Global Acute Myeloid Leukemia Market Revenue (USD Mn), 2018-2026 by Drug Class a. Key Market Findings b. Long Term ROI Segments c. Revenue Opportunity Influencing Factors d. Market Revenue (USD Mn) Assessment and Forecast by Drug Class, 2018-2026 i. Tyrosine Kinase Inhibitors ii. Hedgehog Pathway Inhibitors iii. Topoisomerase 2 Inhibitors iv. Others 8. Global Acute Myeloid Leukemia Market Revenue (USD Mn), 2018-2026 by End User a. Key Market Findings b. Long Term ROI Segments c. Revenue Opportunity Influencing Factors d. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 i. Hospital ii. Clinic iii. Others 9. Global Acute Myeloid Leukemia Market Revenue (USD Mn), 2018-2026 by Region a. Key Market Findings b. Long Term ROI Segments c. Revenue Opportunity Influencing Factors d. Market Revenue (USD Mn) Assessment and Forecast by Region,2026 i. North America ii. Latin America iii. Europe iv. Asia Pacific v. Rest of world 10. North America Acute Myeloid Leukemia Market Revenue (US$ Mn), 20182026 a. Key Market Findings b. Long Term ROI Segments c. Revenue Opportunity Influencing Factors d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026 i. US ii. Canada e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class, 2018-2026 i. Tyrosine Kinase Inhibitors ii. Hedgehog Pathway Inhibitors iii. Topoisomerase 2 Inhibitors iv. Others f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 i. Hospital ii. Clinic iii. Others 11. Latin America Acute Myeloid Leukemia Market Revenue (US$ Mn), 20182026 a. Key Market Findings b. Long Term ROI Segments c. Revenue Opportunity Influencing Factors d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026 i. Brazil ii. Mexico iii. Argentina iv. Rest of Latin America e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class, 2018-2026 i. Tyrosine Kinase Inhibitors ii. Hedgehog Pathway Inhibitors iii. Topoisomerase 2 Inhibitors iv. Others f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 i. Hospital ii. Clinic iii. Others 12. Europe America Acute Myeloid Leukemia Market Revenue (US$ Mn), 20182026 a. Key Market Findings b. Long Term ROI Segments c. Revenue Opportunity Influencing Factors d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026 i. Germany ii. France iii. Spain iv. UK v. Russia vi. Poland vii. Rest of Europe e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class, 2018-2026 i. Tyrosine Kinase Inhibitors ii. Hedgehog Pathway Inhibitors iii. Topoisomerase 2 Inhibitors iv. Others f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 i. Hospital ii. Clinic iii. Others 13. Asia Pacific America Acute Myeloid Leukemia Market Revenue (US$ Mn), 2018-2026 a. Key Market Findings b. Long Term ROI Segments c. Revenue Opportunity Influencing Factors d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026 i. Emerging Asia 1. China 2. India 3. ASEAN-5 4. Rest of Emerging Asia ii. Japan e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class, 2018-2026 i. Tyrosine Kinase Inhibitors ii. Hedgehog Pathway Inhibitors iii. Topoisomerase 2 Inhibitors iv. Others f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 i. Hospital ii. Clinic iii. Others 14. Rest of World America Acute Myeloid Leukemia Market Revenue (US$ Mn), 2018-2026 a. Key Market Findings b. Long Term ROI Segments c. Revenue Opportunity Influencing Factors d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026 i. Middle East ii. South Africa iii. North Africa iv. Rest of World e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class, 2018-2026 i. Tyrosine Kinase Inhibitors ii. Hedgehog Pathway Inhibitors iii. Topoisomerase 2 Inhibitors iv. Others f. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 i. Hospital ii. Clinic iii. Others 15. Company Profiles a. Competition Landscape b. Global Company Share (USD Mn) Overview, 2018 c. Company Profiles i. Novartis AG 1. Corporate Overview 2. Financial Performance 3. Peer Comparison & 3C marketing equation 4. Company Strategy & Channel Management ii. Celgene Corporation 1. Corporate Overview 2. Financial Performance 3. Peer Comparison & 3C marketing equation 4. Company Strategy & Channel Management iii. Astellas Pharma Inc. 1. Corporate Overview 2. Financial Performance 3. Peer Comparison & 3C marketing equation 4. Company Strategy & Channel Management iv. Agios Pharmaceuticals, Inc. 1. Corporate Overview 2. Financial Performance 3. Peer Comparison & 3C marketing equation 4. Company Strategy & Channel Management v. Polaris group 1. Corporate Overview 2. Financial Performance 3. Peer Comparison & 3C marketing equation 4. Company Strategy & Channel Management vi. Otsuka Pharmaceutical Co., Ltd. 1. Corporate Overview 2. Financial Performance 3. Peer Comparison & 3C marketing equation 4. Company Strategy & Channel Management vii. Actinium Pharmaceuticals, Inc. 1. Corporate Overview 2. Financial Performance 3. Peer Comparison & 3C marketing equation 4. Company Strategy & Channel Management viii. Amgen Inc. 1. Corporate Overview 2. Financial Performance 3. Peer Comparison & 3C marketing equation 4. Company Strategy & Channel Management 16. Research Sources & Primary Verbatim Inquire further details about this report at: [email protected] About FutureWise Research: We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future. Contact Us: Company Name: FutureWise Research Contact Person: Vinay Thaploo Email: [email protected] Phone: +44 141 628 9353 / +1 970 279 4295 City: Leeds Country: United Kingdom Website: www.futurewiseresearch.com
The global acute myeloid leukaemia market is poised to value over US$ 1.5 billion by the end of 2026 and registering a CAGR of over 12% during the forecast period, 2019 to 2026
© Copyright 2024 Paperzz
